Mark Voll
Known title: Chief Financial OfficerCIK: 0001207512
Mark Voll's purchase track record
Mark Voll has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/19/2026 | RNXT | $20K | +45.2% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RNXT | ▲ Buy | Grant | 80,000 | $0 | 9/10/2026 | View on chart |
| RNXT | ▲ Buy | Open Market | 25,000 | $20K | 5/19/2026 | View on chart |
| RNXT | ▲ Buy | Grant | 80,000 | $0 | 4/3/2026 | View on chart |
| RNXT | ▲ Buy | Grant | 12,380 | $0 | 3/25/2026 | View on chart |
| RNXT | ▲ Buy | Open Market | 97,200 | — | 3/20/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
RenovoRx publishes peer-reviewed case series in oncology journal
RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.
RenovoRx publishes peer-reviewed case series in oncology journal. RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.